Laurus Labs
Ticker > Company >

Laurus Labs share price

Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  243k   1k   486

489.25
+0.10 (0.02%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 491.65

Today's Low

₹ 482.45

52 Week High

₹ 517.9

52 Week Low

₹ 358.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 26378.37 Cr.

Enterprise Value

₹ 28384.51 Cr.

No. of Shares

53.92 Cr.

P/E

112.16

P/B

6.18

Face Value

₹ 2

Div. Yield

0.16 %

Book Value (TTM)

₹  79.19

CASH

₹ 42.92 Cr.

DEBT

₹ 2049.06 Cr.

Promoter Holding

27.18 %

EPS (TTM)

₹  4.36

Sales Growth

-16.65%

ROE

5.44 %

ROCE

7.54%

Profit Growth

-70.58 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 22 Indices.

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
41072.05
  -76.8499999999985 (-0.186760763957239%)

NIFTY500

Nifty 500
21820.85
  -183.5 (-0.833926019173481%)

NIFTYPHARMA

Nifty Pharma
21740.1
  -28.75 (-0.13206944785783%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
18989.75
  -86.25 (-0.452138813168379%)

NIFTYSMALL

NIFTY Smallcap 100
17596.6
  -80.75 (-0.456799237442262%)

NIFTYSMALLCAP250

Nifty Smallcap 250
16747.85
  -97.4000000000015 (-0.578204538371363%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15270.4
  -112.75 (-0.732944812993441%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14330.7
  -89.2999999999993 (-0.619278779472954%)

NIFTYHEALTH

Nifty Healthcare Index
13816.05
  -22.9000000000015 (-0.165474981844727%)

NIFTYTOTALMCAP

NIFTY Total Market
12302.6
  -103.449999999999 (-0.833867346979889%)

NIFTYSMALLCAP50

Nifty Smallcap 50
8513.5
  -22.6000000000004 (-0.264757910521207%)

NFT500EQUAL

Nifty 500 Equal Weight
13586.01
  -137.629999999999 (-1.00286804375515%)

NIFTYFULLSMALLCAP100

NIFTY FULL SMALLCAP100
4000.01
  -72.2099999999996 (-1.77323425551663%)

MIDCAP

Bse MidCap
44467.99
  -162.970000000001 (-0.365150111043999%)

BSE HC

Bse Healthcare
42447.07
  46.9599999999991 (0.11075442964652%)

BSE500

Bse 500
34361.41
  -289.419999999998 (-0.835246947908597%)

MID150

Bse 150 MidCap Index
15286.7
  -56.0499999999993 (-0.365319124667995%)

MSL400

Bse 400 MidSmallCap Index
11623.42
  -57.1299999999992 (-0.489103680905434%)

LMI250

Bse 250 LargeMidCap Index
10169.78
  -87.0299999999988 (-0.848509429344979%)

ALLCAP

Bse Allcap
10471.31
  71.0699999999997 (0.683349615008888%)

S&P LARGEMIDCAP

Bse LargeMidCap
10057.64
  -87.880000000001 (-0.866195128490221%)

S&P MIDSMLCAP

Bse MidSmallCap
12896.2
  -67.5599999999995 (-0.521145099878428%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-16.65%
3 Year0.3%
5 Year16.57%

Profit Growth

1 Year-70.58%
3 Year-38.38%
5 Year18.68%

ROE%

1 Year5.44%
3 Year16.86%
5 Year21.72%

ROCE %

1 Year7.54%
3 Year17.78%
5 Year21.27%

Debt/Equity

0.4895

Price to Cash Flow

40.06

Interest Cover Ratio

2.9989

CFO/PAT (5 Yr. Avg.)

1.15042622906473

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 27.18 0.00
Jun 2024 27.18 0.00
Mar 2024 27.19 0.00
Dec 2023 27.19 0.04
Sep 2023 27.20 0.04
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 24.1195722616177% in the last 5 years.
  • The company has a good cash flow management; CFO/PAT stands at 1.15042622906473.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 6.59551647559923.

 Limitations

  • The company has shown a poor profit growth of -38.3803290959083% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.304322990968076% for the Past 3 years.
  • The company is trading at a high PE of 112.16.
  • The company is trading at a high EV/EBITDA of 34.0778.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 1158.03 1132.19 1414.52 1116.93 1184.85
Total Expenditure 977.52 961.81 1143.41 955.54 1003.02
Operating Profit 180.51 170.38 271.11 161.39 181.83
Other Income 5.9 10.72 24.09 9.3 11.89
Interest 37.8 37.56 41.99 40.89 44.69
Depreciation 85.4 86.84 88.9 91 90.94
Exceptional Items 0 0 0 0 0
Profit Before Tax 63.21 56.7 164.31 38.8 58.09
Tax 16.54 14.06 42.99 10.02 15.65
Profit After Tax 46.67 42.64 121.32 28.78 42.44
Adjusted EPS (Rs) 0.87 0.79 2.25 0.53 0.79

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2797.34 4768.72 4707.04 5773.45 4812.39
Total Expenditure 2227.11 3258.85 3421.84 4291.69 4062.51
Operating Profit 570.23 1509.87 1285.2 1481.76 749.88
Other Income 5.81 27.32 21.55 15.95 47.42
Interest 87.71 65.92 95.86 145.7 150.82
Depreciation 183.85 196.64 235.48 300.58 345.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 304.48 1274.63 975.41 1051.43 301.47
Tax 37.43 318.52 225.32 291.05 77.77
Net Profit 267.05 956.11 750.09 760.38 223.7
Adjusted EPS (Rs.) 5 17.82 13.96 14.12 4.15

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 106.91 107.32 107.47 107.73 107.79
Total Reserves 1708.89 2604.92 3280.74 3949.09 4099.26
Borrowings 165 382.64 549.67 565.49 490.53
Other N/C liabilities 52.08 178.68 236.55 229.33 234.11
Current liabilities 1636.72 2696.26 2899.57 2844.09 3545.04
Total Liabilities 3669.6 5969.82 7074 7695.73 8476.73
Assets
Net Block 1694.18 1818.04 2186.23 2884.16 3036.31
Capital WIP 66.53 324.17 755.03 357.06 155.51
Intangible WIP 0 0 0 0 0
Investments 58.32 318.89 361.72 384.12 634.87
Loans & Advances 39.42 91.84 69.82 132.84 292.11
Other N/C Assets 26.51 30.8 31.16 28.52 31.57
Current Assets 1784.64 3386.08 3670.04 3909.03 4326.36
Total Assets 3669.6 5969.82 7074 7695.73 8476.73
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 304.48 1274.63 975.41 1051.43 301.47
Adjustment 288.19 240.43 322.36 442.51 478.32
Changes in Assets & Liabilities -208.54 -594.55 -308.46 -344.26 -23.27
Tax Paid -39.45 -226.06 -166.34 -268.13 -97.98
Operating Cash Flow 344.68 694.45 822.97 881.55 658.54
Investing Cash Flow -216.83 -899.68 -836.61 -735.27 -756.74
Financing Cash Flow -127.48 243.13 15.19 -185.19 139.41
Net Cash Flow 0.37 37.9 1.55 -38.91 41.21

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 27.20 27.19 27.19 27.18 27.18
chandrakanth chereddi 0.01 0.01 0.01 0.01 0.01
chava narasimha rao 0.02 0.02 0.02 0.02 0.02
chunduru venkata lakshman... 2.50 2.50 2.50 2.49 2.49
hymavathi vantaram 0.04 0.04 0.04 0.04 0.04
kamala kommana 0.02 0.02 0.02 0.02 0.02
krishnaveni vasireddi 0.04 0.04 0.04 0.04 0.04
m/s. leven holdings (repr... 1.24 1.24 1.24 1.24 1.24
m/s. nsn holdings (repres... 23.04 23.03 23.03 23.02 23.02
nagamani thokala 0.02 0.02 0.02 0.02 0.02
narasimha rao suryadevara... 0.03 0.03 0.03 0.03 0.03
rama suryadevara 0.03 0.03 0.03 0.03 0.03
sekhar babu chunduru 0.02 0.02 0.02 0.02 0.02
venkata ravi kumar vantar... 0.19 0.19 0.19 0.19 0.19
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 72.80 72.81 72.81 72.82 72.82
akash bhanshali 1.33 1.31 1.33 1.33 1.33
amansa holdings private l... 4.05 2.85 2.85 2.21 2.14
anukar projects private l... 3.25 3.24 3.24 3.24 3.24
barclays wealth trustees ... 1.35 1.31 1.23 1.21 1.14
kotak funds - india midca... - 1.25 1.33 1.33 1.39
life insurance corporatio... 2.70 2.70 2.70 2.70 2.70
new world fund inc 5.49 6.45 6.50 6.50 6.50
sbi large & midcap fund - - - - 2.53
smallcap world fund, inc 3.55 4.10 4.10 4.09 4.09
vanguard total internatio... - - - - 1.00
mirae asset elss tax save... - - - 5.24 -
mirae asset large & midca... - - 3.01 - -
tata aia life insurance c... 1.39 1.12 - - -
bandhan multi cap fund 1.02 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Laurus Labs submits analyst meet intimation 7 Nov, 12:43 PM Laurus Labs informs about standalone and consolidated financial results 24 Oct, 5:21 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs inaugurates new R&D facility 16 Sep, 2:59 PM Laurus Labs completes USFDA Audit for API Manufacturing Facility at Hyderabad 14 Sep, 4:47 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs informs about analyst meet 19 Jul, 5:12 PM Laurus Labs informs about press release 19 Jun, 4:32 PM Laurus Labs informs about disclosures 11 Jun, 4:29 PM Laurus Lab informs about approval of audited financial results 25 Apr, 5:12 PM Laurus Labs informs about investors presentation 25 Apr, 4:50 PM Laurus Labs informs about press release 25 Apr, 4:45 PM Laurus Labs reports 30% fall in Q4 consolidated net profit 25 Apr, 4:00 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM USFDA completes inspection at Laurus Labs’ API manufacturing facilities 19 Apr, 6:16 PM Laurus Labs informs about closure of trading window 30 Mar, 10:16 AM Laurus Labs invests over Rs 99 crore in subsidiary 19 Feb, 12:13 PM Laurus Labs informs about updates on acquisition 17 Feb, 3:14 PM Laurus Labs submits analyst meet intimation 13 Feb, 3:56 PM Laurus Labs enters into joint venture agreement with Krka 29 Jan, 12:41 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs informs about board meeting 17 Jan, 3:22 PM USFDA inspects Andhra Pradesh facility of Laurus Labs’ arm 13 Dec, 10:41 AM Laurus Labs informs about investor presentation 25 Nov, 11:53 AM Laurus Labs informs about analyst meeting 22 Nov, 12:28 PM Laurus Labs acquires additional stake in Laurus Bio 21 Nov, 10:30 AM Laurus Labs informs about update on acquisition of shares 21 Nov, 10:24 AM Laurus Labs informs about un-audited financial results 20 Oct, 4:55 PM Laurus Labs reports 83% fall in Q2 consolidated net profit 20 Oct, 3:44 PM Laurus Labs - Quaterly Results 20 Oct, 2:55 PM Laurus Labs - Quaterly Results 20 Oct, 2:55 PM Laurus Labs - Quaterly Results 20 Oct, 2:55 PM Laurus Labs informs about investor meeting 20 Sep, 12:18 PM Laurus Labs to acquire stake in Laurus Bio 12 Sep, 9:49 AM Laurus Labs informs about analyst meet 10 Aug, 10:25 AM Laurus Labs reports 89% fall in Q1 consolidated net profit 27 Jul, 4:13 PM Laurus Labs - Quaterly Results 27 Jul, 2:54 PM Laurus Labs - Quaterly Results 27 Jul, 2:54 PM Laurus Labs - Quaterly Results 27 Jul, 2:54 PM Laurus Labs informs about earnings conference call 21 Jul, 12:39 PM Laurus Labs informs about earnings conference call 21 Jul, 12:35 PM Laurus Labs informs about scrutinizer's report 15 Jul, 11:49 AM

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Laurus Labs and its performance over the period of time. Laurus Labs stock price today is Rs 489.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Laurus Labs cash from the operating activity was Rs 658.54 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Laurus Labs has a Debt to Equity ratio of 0.4895 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Laurus Labs , the EPS growth was -70.5966 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Laurus Labs has OPM of 15.582278244282 % which is a good sign for profitability.
     
  • ROE: Laurus Labs have a poor ROE of 5.436 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Laurus Labs is Rs 489.15. One can use valuation calculators of ticker to know if Laurus Labs share price is undervalued or overvalued.
Last Updated on:
Brief about Laurus Labs

Laurus Labs Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Laurus Labs Ltd. is a renowned pharmaceutical company that specializes in the research, development, and manufacturing of generic APIs (Active Pharmaceutical Ingredients) and research and development (R&D) services to the global pharmaceutical industry. Here, we will delve into Laurus Labs Ltd.'s various aspects, including its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders. This analysis is tailored specifically for long-term stock investors seeking comprehensive stock evaluation. Additionally, we will highlight the use of Ticker pre-built screening tools that support fair value calculation through DCF (Discounted Cash Flow) Analysis, BVPS (Book Value per Share) Analysis, Earnings Multiple Approach, and DuPont Analysis.

Laurus Labs Ltd Share Price

Laurus Labs Ltd.'s share price is a key parameter for investors interested in long-term stock analysis. It is crucial to monitor and track the company's share price, which can be done through our trading platform. Laurus Labs Ltd. is traded on various stock exchanges, such as the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange), and investing in its shares can be done through these exchanges.

Laurus Labs Ltd Balance Sheet

The balance sheet is an essential financial statement that provides insights into Laurus Labs Ltd.'s assets, liabilities, and shareholder's equity at a particular point in time. It serves as a snapshot of the company's financial health and stability and is of utmost importance to long-term investors. Ticker innovative screening tools enable investors to calculate fair value using DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, thereby empowering them to make informed investment decisions.

Laurus Labs Ltd Annual Report

Laurus Labs Ltd.'s annual report is a comprehensive document that offers details about the company's performance, strategies, and governance in the preceding year. Ticker simplifies access to these annual reports, making them easily downloadable for investors' convenience. Studying the annual reports is crucial as it provides insights into the company's business model, growth trajectory, and future plans, enabling investors to gain a deeper understanding of Laurus Labs Ltd.

Laurus Labs Ltd Dividend

As a reputable company, Laurus Labs Ltd. values its shareholders and regularly distributes dividends to them. Dividends are a portion of the company's profits paid out to shareholders as a return on their investment. At our platform, investors can explore the company's dividend history and stay updated on the latest dividend announcements.

Laurus Labs Ltd Quarterly Results

To analyze Laurus Labs Ltd.'s financial performance over specific periods, it is necessary to review the company's quarterly results. Ticker offers a range of tools and resources to facilitate this analysis. Investors can access quarterly reports, utilize analytical tools, and employ pre-built screening tools to assess the company's growth trends, profitability, and overall financial stability.

Laurus Labs Ltd Stock Price

Monitoring stock prices is pivotal for investors aiming to buy or sell shares of Laurus Labs Ltd. Ticker platform delivers real-time stock price data, ensuring that investors have access to the latest information to make informed decisions. Along with the stock price, investors can closely track its fluctuations, historical trends, and trading volumes to evaluate the stock's performance.

Laurus Labs Ltd Price Chart

Price charts provide graphical representations of a stock's historical price movements, helping investors identify trends and patterns. Ticker offers comprehensive price charts of Laurus Labs Ltd., allowing investors to visualize the stock's performance over time.

Laurus Labs Ltd News

Keeping abreast of the latest news about Laurus Labs Ltd. is vital for long-term investors. Our platform provides up-to-date news, including market changes, corporate announcements, industry developments, and other relevant events that may impact the stock market. Investors can access these news updates to stay informed and make well-informed investment decisions.

Laurus Labs Ltd Concall Transcripts

Conference call transcripts provide valuable insights into Laurus Labs Ltd.'s management discussions regarding financial results, operational strategies, and future plans. By offering access to concall transcripts, our platform ensures that investors have access to first-hand information about the company's direction and future prospects.

Laurus Labs Ltd Investor Presentations

Laurus Labs Ltd. presents its corporate strategies, financial performance, and future projections through investor presentations. These presentations offer a glimpse into the company's growth plans, market positioning, and operational strategies. Ticker provides the facility to download these presentations, enabling investors to make well-informed decisions based on a comprehensive understanding of the company's objectives.

Laurus Labs Ltd Promoters

Promoters play a pivotal role in the success of Laurus Labs Ltd. They are individuals or entities responsible for starting the company, raising capital, and maintaining management control. Understanding the promoters' vision, strategies, and plans for the company's future is integral to evaluating the investment potential of Laurus Labs Ltd.

Laurus Labs Ltd Shareholders

Shareholders are critical stakeholders in any company. They provide the necessary capital and possess ownership through shares. Identifying the major shareholders of Laurus Labs Ltd., along with their respective stakes and voting power, is indispensable for assessing the company's governance structure and overall stability.

Laurus Labs Ltd ROCE

Laurus Labs Ltd ROCE (Return on Capital Employed) is a vital financial ratio used to evaluate the company's profitability in relation to the capital it employs. By analyzing the ROCE data available in the financials table or ratio section above, investors can gain insights into how effectively Laurus Labs Ltd generates returns on its capital investments. This ratio serves as a key indicator of the company's capital efficiency and overall profitability, making it an essential metric for stock analysis.

Laurus Labs Ltd EBITDA

Laurus Labs Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a significant financial measure that reflects the company's operational profitability. By excluding non-operating expenses, the EBITDA data available in the financials table or ratio section above provides insights into Laurus Labs Ltd's core business performance and operational efficiency.

Laurus Labs Ltd DPS

Laurus Labs Ltd DPS (Dividends Per Share) represents the cash distributed to shareholders for each share held in the company. Investors can evaluate Laurus Labs Ltd's dividend policy and potential returns by referring to the DPS data available in the financials table or ratio section above. This metric is particularly important for those seeking regular income from their investments.

Laurus Labs Ltd EPS

Laurus Labs Ltd EPS (Earnings Per Share) is a fundamental metric that indicates the company's profitability on a per-share basis. By analyzing the EPS data available in the financials table or ratio section above, investors can assess Laurus Labs Ltd's earning potential and performance. EPS is a significant measure used to evaluate the value and growth potential of the company's stock.

Read More
X